메뉴 건너뛰기




Volumn 42, Issue 6, 2015, Pages 685-695

Randomised clinical trial: A dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; GASTRIN; GLUCOSE; LANSOPRAZOLE; PEPSINOGEN I; PEPSINOGEN II; PROTEIN; TRIACYLGLYCEROL; URIC ACID; VONOPRAZAN; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

EID: 84939568162     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13331     Document Type: Article
Times cited : (130)

References (33)
  • 1
    • 0030962574 scopus 로고    scopus 로고
    • Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
    • Chiba N, De Gara CJ, Wilkinson JM, et al,. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
    • (1997) Gastroenterology , vol.112 , pp. 1798-1810
    • Chiba, N.1    De Gara, C.J.2    Wilkinson, J.M.3
  • 2
    • 0141539363 scopus 로고    scopus 로고
    • Short-term treatment of gastroesophageal reflux disease
    • van Pinxteren B, Numans ME, Lau J, et al,. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003; 18: 755-63.
    • (2003) J Gen Intern Med , vol.18 , pp. 755-763
    • Van Pinxteren, B.1    Numans, M.E.2    Lau, J.3
  • 3
    • 68949204296 scopus 로고    scopus 로고
    • Systematic review: Standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - A mixed treatment comparison of randomized controlled trials
    • Edwards SJ, Lind T, Lundell L, et al,. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis-a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther 2009; 30: 547-56.
    • (2009) Aliment Pharmacol Ther , vol.30 , pp. 547-556
    • Edwards, S.J.1    Lind, T.2    Lundell, L.3
  • 4
    • 14644421531 scopus 로고    scopus 로고
    • Efficacy of esomeprazole 40 mg vs. Lansoprazole 30 mg for healing moderate to severe erosive oesophagitis
    • Fennerty MB, Johanson JF, Hwang C, et al,. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005; 21: 455-63.
    • (2005) Aliment Pharmacol Ther , vol.21 , pp. 455-463
    • Fennerty, M.B.1    Johanson, J.F.2    Hwang, C.3
  • 5
    • 0034949404 scopus 로고    scopus 로고
    • The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety
    • Vakil NB, Shaker R, Johnson DA, et al,. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-35.
    • (2001) Aliment Pharmacol Ther , vol.15 , pp. 927-935
    • Vakil, N.B.1    Shaker, R.2    Johnson, D.A.3
  • 6
    • 78649908709 scopus 로고    scopus 로고
    • Novel approaches to inhibition of gastric acid secretion
    • Sachs G, Shin JM, Hunt R,. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 2010; 12: 437-47.
    • (2010) Curr Gastroenterol Rep , vol.12 , pp. 437-447
    • Sachs, G.1    Shin, J.M.2    Hunt, R.3
  • 7
    • 4344654345 scopus 로고    scopus 로고
    • Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: A randomized, three-way crossover study
    • Katz PO, Castell DO, Chen Y, et al,. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20: 399-406.
    • (2004) Aliment Pharmacol Ther , vol.20 , pp. 399-406
    • Katz, P.O.1    Castell, D.O.2    Chen, Y.3
  • 8
    • 46749088691 scopus 로고    scopus 로고
    • Nocturnal gastroesophageal reflux disease: Issues, implications, and management strategies
    • Johnson DA, Katz PO,. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev Gastroenterol Disord 2008; 8: 98-108.
    • (2008) Rev Gastroenterol Disord , vol.8 , pp. 98-108
    • Johnson, D.A.1    Katz, P.O.2
  • 9
    • 0037380492 scopus 로고    scopus 로고
    • Pharmacogenetics of the proton pump inhibitors: A systematic review
    • Chong E, Ensom MHH,. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71.
    • (2003) Pharmacotherapy , vol.23 , pp. 460-471
    • Chong, E.1    Ensom, M.H.H.2
  • 10
    • 25644459349 scopus 로고    scopus 로고
    • Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies
    • Furuta T, Shirai N, Sugimoto M, et al,. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
    • (2005) Drug Metab Pharmacokinet , vol.20 , pp. 153-167
    • Furuta, T.1    Shirai, N.2    Sugimoto, M.3
  • 11
    • 28144433010 scopus 로고    scopus 로고
    • Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseases
    • Andersson K, Carlsson E,. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294-307.
    • (2005) Pharmacol Ther , vol.108 , pp. 294-307
    • Andersson, K.1    Carlsson, E.2
  • 12
    • 0027053361 scopus 로고
    • Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients
    • Cederberg C, Lind T, Röhss K, et al,. Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients. Digestion 1992; 53: 171-8.
    • (1992) Digestion , vol.53 , pp. 171-178
    • Cederberg, C.1    Lind, T.2    Röhss, K.3
  • 13
    • 0032737083 scopus 로고    scopus 로고
    • Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion
    • Dammann HG, Burkhardt F,. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999; 11: 1277-82.
    • (1999) Eur J Gastroenterol Hepatol , vol.11 , pp. 1277-1282
    • Dammann, H.G.1    Burkhardt, F.2
  • 14
    • 84861028397 scopus 로고    scopus 로고
    • Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methymethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB)
    • Arikawa Y, Nishida H, Kurasawa O, et al,. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methymethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem 2012; 55: 4446-56.
    • (2012) J Med Chem , vol.55 , pp. 4446-4456
    • Arikawa, Y.1    Nishida, H.2    Kurasawa, O.3
  • 15
    • 80054787732 scopus 로고    scopus 로고
    • Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol 3-yl]-N-methylmethanamine monofumarate (TAK-438)
    • Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol 3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
    • (2011) J Pharmacol Exp Ther , vol.339 , pp. 412-420
    • Shin, J.M.1    Inatomi, N.2    Munson, K.3
  • 16
    • 79953716223 scopus 로고    scopus 로고
    • A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
    • Matsukawa J, Hori Y, Nishida H, et al,. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 2011; 81: 1145-51.
    • (2011) Biochem Pharmacol , vol.81 , pp. 1145-1151
    • Matsukawa, J.1    Hori, Y.2    Nishida, H.3
  • 17
    • 79956193494 scopus 로고    scopus 로고
    • A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals
    • Hori Y, Matsukawa J, Tekeuchi T, et al,. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011; 337: 797-804.
    • (2011) J Pharmacol Exp Ther , vol.337 , pp. 797-804
    • Hori, Y.1    Matsukawa, J.2    Tekeuchi, T.3
  • 18
    • 77957228369 scopus 로고    scopus 로고
    • 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases
    • Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
    • (2010) J Pharmacol Exp Ther , vol.335 , pp. 231-238
    • Hori, Y.1    Imanishi, A.2    Matsukawa, J.3
  • 19
    • 37849036310 scopus 로고    scopus 로고
    • A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease
    • Dent J, Kahrilas PJ, Hatlebakk J, et al,. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103: 20-6.
    • (2008) Am J Gastroenterol , vol.103 , pp. 20-26
    • Dent, J.1    Kahrilas, P.J.2    Hatlebakk, J.3
  • 20
    • 84989307721 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects
    • Sakurai Y, Nishimura A, Kennedy G, et al,. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6: e94. doi: 10.1038/ctg.2015.18
    • (2015) Clin Transl Gastroenterol , vol.6 , pp. e94
    • Sakurai, Y.1    Nishimura, A.2    Kennedy, G.3
  • 21
    • 84964207179 scopus 로고    scopus 로고
    • Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
    • Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
    • (2015) Aliment Pharmacol Ther , vol.41 , pp. 636-648
    • Jenkins, H.1    Sakurai, Y.2    Nishimura, A.3
  • 22
    • 0029933079 scopus 로고    scopus 로고
    • The endoscopic assessment of esophagitis: A progress report on observer agreement
    • Armstrong D, Bennett JR, Blum AL, et al,. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
    • (1996) Gastroenterology , vol.111 , pp. 85-92
    • Armstrong, D.1    Bennett, J.R.2    Blum, A.L.3
  • 23
    • 0027973846 scopus 로고
    • Mantel-Haenszel-type tests for testing equivalence or more than equivalence in comparative clinical trial
    • Yanagawa T, Tango T, Hiejima Y,. Mantel-Haenszel-type tests for testing equivalence or more than equivalence in comparative clinical trial. Biometrics 1994; 50: 859-64.
    • (1994) Biometrics , vol.50 , pp. 859-864
    • Yanagawa, T.1    Tango, T.2    Hiejima, Y.3
  • 24
    • 34848832890 scopus 로고    scopus 로고
    • A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)
    • Kalaitzakis E, Björnsson E,. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag 2007; 3: 653-63.
    • (2007) Ther Clin Risk Manag , vol.3 , pp. 653-663
    • Kalaitzakis, E.1    Björnsson, E.2
  • 25
    • 10744220360 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers
    • Yu KS, Bae KS, Shon JH, et al,. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol 2004; 44: 73-82.
    • (2004) J Clin Pharmacol , vol.44 , pp. 73-82
    • Yu, K.S.1    Bae, K.S.2    Shon, J.H.3
  • 26
    • 36549032595 scopus 로고    scopus 로고
    • A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis
    • Kahrilas PJ, Dent J, Luaritsen K, et al,. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 1385-91.
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 1385-1391
    • Kahrilas, P.J.1    Dent, J.2    Luaritsen, K.3
  • 27
    • 0026803020 scopus 로고
    • Appropriate acid suppression for the management of gastro-oesophageal reflux disease
    • Bell NJV, Burget D, Howden CW, et al,. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
    • (1992) Digestion , vol.51 , pp. 59-67
    • Bell, N.J.V.1    Burget, D.2    Howden, C.W.3
  • 28
    • 67449088166 scopus 로고    scopus 로고
    • Epidemiology and clinical characteristics of GERD in the Japanese population
    • Fujiwara Y, Arakawa T,. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009; 44: 518-34.
    • (2009) J Gastroenterol , vol.44 , pp. 518-534
    • Fujiwara, Y.1    Arakawa, T.2
  • 29
    • 84879616935 scopus 로고    scopus 로고
    • Is proton pump inhibitor therapy for reflux esophagitis sufficient?: A large real-world survey of Japanese patients
    • Higuchi K, Joh T, Nakada K, et al,. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients. Intern Med 2013; 52: 1447-54.
    • (2013) Intern Med , vol.52 , pp. 1447-1454
    • Higuchi, K.1    Joh, T.2    Nakada, K.3
  • 30
    • 84866234607 scopus 로고    scopus 로고
    • Gastric carcinoids after long-term use of a proton pump inhibitor
    • Jianu CS, Fossmark R, Viset T, et al,. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36: 644-9.
    • (2012) Aliment Pharmacol Ther , vol.36 , pp. 644-649
    • Jianu, C.S.1    Fossmark, R.2    Viset, T.3
  • 31
    • 77953198919 scopus 로고    scopus 로고
    • Safety of the long-term use of proton pump inhibitors
    • Thomson AB, Sauve MD, Kassam N, et al,. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16: 2323-30.
    • (2010) World J Gastroenterol , vol.16 , pp. 2323-2330
    • Thomson, A.B.1    Sauve, M.D.2    Kassam, N.3
  • 32
    • 84903627362 scopus 로고    scopus 로고
    • Neuroendocrine pathology of the stomach: The Parma contribution
    • Bordi C,. Neuroendocrine pathology of the stomach: the Parma contribution. Endocr Pathol 2014; 25: 171-80.
    • (2014) Endocr Pathol , vol.25 , pp. 171-180
    • Bordi, C.1
  • 33
    • 67651097918 scopus 로고    scopus 로고
    • Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen i and pepsinogen II in a random adult population
    • Agréus L, Storskrub T, Aro P, et al,. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009; 44: 564-70.
    • (2009) Scand J Gastroenterol , vol.44 , pp. 564-570
    • Agréus, L.1    Storskrub, T.2    Aro, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.